PBAC's latest decision on Olmesartan medoxomil, amlodipine, hydrochlorothiazide: Recommended (2013). Considered for Treatment of hypertension in patients whose blood pressure is not adequately controlled by two of the following: an angiotensin II receptor antagonist, a dihydropyridine calcium channel blocker, or a diuretic.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2013
Submissions
1
2013 → 2013
Eligible population
Patients with hypertension whose blood pressure is not adequately controlled with two of the following: an angiotensin II receptor antagonist, a dihydropyridine calcium channel blocker, or a diuretic.
Therapy area
Cardiovascular
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Seated diastolic blood pressure and seated systolic blood pressure reduction